PRECIGEN, INC. Contract Liability (Deferred Revenue)
PRECIGEN, INC. (PGEN) had Contract Liability (Deferred Revenue) of $284.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-04
- 2026-06-30: Contract with Customer, Liability, Current $284.00K.
- 2026-03-31: Contract with Customer, Liability, Current $410.00K.
- 2025-12-31: Contract with Customer, Liability, Current $517.00K.
- 2025-09-30: Contract with Customer, Liability, Current $480.00K.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2026-06-30 | $284.00K 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $410.00K 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $517.00K 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $480.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $413.00K 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $549.00K 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $589.00K 10-K · filed 2026-03-25 | |
| 2024-09-30 | $407.00K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $378.00K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $407.00K 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $509.00K 10-K · filed 2025-03-19 | |
| 2023-09-30 | $509.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $15.00K 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $15.00K 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $25.00K 10-K · filed 2024-03-19 | |
| 2022-09-30 | $76.00K 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $164.00K 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $2.67M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $1.49M 10-K · filed 2023-03-06 | $4.44M 10-K · filed 2022-03-01 |
| 2021-09-30 | $3.69M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $3.28M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $3.85M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $2.80M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $4.14M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $6.59M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $11.14M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $5.70M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $12.76M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $16.59M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $17.15M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $11.09M 10-K · filed 2020-03-02 | $15.55M 10-K · filed 2019-03-01 |
| 2018-09-30 | $38.04M 10-Q · filed 2018-11-08 | |
| 2017-12-31 | $42.87M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |